CRNX insider trading
NasdaqGS HealthcareCrinetics Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Company website: www.crinetics.com
CRNX insider activity at a glance
FilingIQ has scored 390 insider transactions for CRNX since Jul 18, 2018. The most recent filing in our index is dated Apr 8, 2026.
Across the full history, 17 open-market purchases
and 181 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CRNX insider trades is 57.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CRNX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding CRNX
Frequently asked
- How many insider trades does FilingIQ track for CRNX?
- FilingIQ tracks 390 Form 4 insider transactions for CRNX (Crinetics Pharmaceuticals, Inc.), covering filings from Jul 18, 2018 onwards. 27 of those were filed in the last 90 days.
- Are CRNX insiders net buyers or net sellers?
- Across the full Form 4 history for CRNX, 17 transactions (4%) were open-market purchases and 181 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CRNX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CRNX in?
- Crinetics Pharmaceuticals, Inc. (CRNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.45B.
Methodology & sources
Every CRNX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.